| abstract |
The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; and R ° is hydrogen or C1-2 alkyl; R1a is selected from CONH2; CO2H; an optionally substituted acyclic C1-8 hydrocarbon group; and a monocyclic, carbocyclic or heterocyclic group optionally substituted with 3 to 7 member rings, from which 0, 1, 2, 3 or 4 member rings with a heteroatom selected from O, N and S, R²a group, R²a, is selected of an optionally substituted acyclic d-8 hydrocarbon group; a monocyclic, carbocyclic or heterocyclic group optionally substituted with a 3- to 7-membered ring, of which from the ring the 0.1 or 2-membered ring are rings with a heteroatom selected from O, N and S; and a bicyclic herrocyclic group optionally substituted with a 9 or 10 member ring, of which the 1 or 2 member rings are nitrogen atoms; wherein at least one of R1 and R2 is another of hydrogen; R3 is a 3-to 10-membered monocyclic or bicyclic, carbocyclic or heterocyclic ring optionally substituted containing a 0, 1, 2 or 3-membered ring with a heteroatom selected from N, O and S; R4a is selected from the halogen; cyano; C1-4 alkyl optionally substituted with one or more fluorite atoms; C1-4 alkoxy optionally substituted with one or more fluorite atoms; hydroxy-C1-4 alkyl; and C1-2 C1-4 alkoxy; R5 is selected from hydrogen and a substituent R5a; and R 5 is selected from C1-2 alkyl optionally substituted with one or more fluorite atoms; C1-3 alkoxy optionally substituted with one or more fluorite atoms; halogen, cyclopropyl; cyano and amino. The compounds have activity against the hepatitis C virus and can be used in the prevention or treatment of viral hepatitis C infections. |